brimonidine + timolol + latanoprost

Brimonidine + timolol + latanoprost is a combination therapy regimen used for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. This regimen typically involves the administration of a fixed-dose combination of brimonidine tartrate (an alpha-2 adrenergic agonist) and timolol maleate (a non-selective beta-adrenergic antagonist), such as Combigan, in conjunction with latanoprost (a prostaglandin F2α analogue). The mechanism of action is multi-modal: brimonidine reduces aqueous humor production and enhances uveoscleral outflow; timolol decreases aqueous humor secretion by the ciliary epithelium; and latanoprost increases the outflow of aqueous humor via the uveoscleral pathway. Genovate Biotechnology Co., Ltd. sponsored clinical evaluations (e.g., NCT00943111) to assess the safety and efficacy of this triple-drug approach in patients who were insufficiently controlled on latanoprost monotherapy.

Brand names

CombiganXalatanGenoprost

Other names

Brimonidine/Timolol/Latanoprost Combination TherapyBrimonidine tartrate + Timolol maleate + Latanoprost